Jan Lehmann

Kiel, SH 24116, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.

Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.

Journal: European urology

Published: June 23, 2025

Long-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour type.

Long-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour type.

Journal: Journal of cancer survivorship : research and practice

Published: February 01, 2024

Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)].

Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)].

Journal: European urology oncology

Published: October 09, 2023

Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.

Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.

Journal: European urology oncology

Published: May 20, 2023

Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis.

Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis.

Journal: ClinicoEconomics and outcomes research : CEOR

Published: January 06, 2023

Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.

Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.

Journal: Urologic oncology

Published: December 16, 2022

Factors influencing the choice of androgen deprivation therapy for patients with hormone-sensitive prostate cancer : Results of the ProComD study

Factors influencing the choice of androgen deprivation therapy for patients with hormone-sensitive prostate cancer : Results of the ProComD study

Journal: Der Urologe. Ausg. A

Published: July 13, 2021

Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort.

Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 24, 2021

CARD study: relevance for the treatment of advanced prostate cancer

CARD study: relevance for the treatment of advanced prostate cancer

Journal: Aktuelle Urologie

Published: September 24, 2020

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.

Journal: European urology

Published: July 26, 2018

A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer.

A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer.

Journal: Journal of cancer research and clinical oncology

Published: July 24, 2018

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 17, 2018

Showing 1-12 of 27

Last Updated: 09/26/2026